Randall K. Johnson

Dr. Johnson joins Callisto after an extensive career in the area of cancer drug development. With over 30 years of experience in government and industry in cancer drug discovery and development, Dr. Johnson is also a co-author on 200 scientific papers and an inventor on 14 issued U.S. patents. During his 20 year career at SmithKline Beecham Pharmaceuticals (eventually GlaxoSmithKline), Dr. Johnson headed the cancer drug discovery effort and also was responsible for setting up centralized high throughput screening. Dr. Johnson was responsible for the discovery and development of topotecan, which has been marketed worldwide for the treatment of ovarian and lung cancers. He is currently an independent consultant in oncology and has, in the past 3 years, provided advice and guidance to over 60 clients in the venture capital, biotechnology and pharmaceutical industries. Dr. Johnson is a member of the Scientific Advisory Boards of seven biotechnology companies in the U.S., Europe and Asia.